Cargando…

Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients

PURPOSE: Liquid biopsy offers an attractive platform for noninvasive tumor diagnosis, prognostication, and prediction of glioblastoma clinical outcomes. Prior studies report that 30% to 50% of GBM lesions characterized by EGFR amplification also harbor the EGFRvIII mutation. EXPERIMENTAL DESIGN: A n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Batool, Syeda Maheen, Muralidharan, Koushik, Hsia, Tiffany, Falotico, Sarah, Gamblin, Austin S., Rosenfeld, Yulia B., Khanna, Sirena K., Balaj, Leonora, Carter, Bob S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475243/ https://www.ncbi.nlm.nih.gov/pubmed/35849415 http://dx.doi.org/10.1158/1078-0432.CCR-22-0444

Ejemplares similares

Decoding vesicle-based precision oncology in gliomas
por: Batool, Syeda Maheen, et al.
Publicado: (2022)

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
por: Sahin, Ayguen, et al.
Publicado: (2018)

EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

Glioblastoma‐derived extracellular vesicle subpopulations following 5‐aminolevulinic acid treatment bear diagnostic implications
por: Hsia, Tiffaney, et al.
Publicado: (2022)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021)

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene
por: Włodarczyk, Aneta, et al.
Publicado: (2022)

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
por: Shen, Ying, et al.
Publicado: (2015)

Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma
por: Wheeler, Sarah E., et al.
Publicado: (2015)

EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma
por: NOZAWA, Takanori, et al.
Publicado: (2019)

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
por: Choi, Justin, et al.
Publicado: (2022)

Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models
por: Li, You, et al.
Publicado: (2020)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
por: Struve, Nina, et al.
Publicado: (2015)

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
por: Velpula, Kiran K., et al.
Publicado: (2017)

Systematic Review of Photodynamic Therapy in Gliomas
por: Hsia, Tiffaney, et al.
Publicado: (2023)

Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging
por: Liu, Kaiyu, et al.
Publicado: (2015)

Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis
por: Kang, Keiko M., et al.
Publicado: (2021)

A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII
por: Trembath, Dimitri G, et al.
Publicado: (2007)

Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation
por: Stec, Wojciech, et al.
Publicado: (2018)

LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis
por: Luo, Chang-Liang, et al.
Publicado: (2018)

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies
por: Ellwanger, Kristina, et al.
Publicado: (2017)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells
por: Yin, Jinlong, et al.
Publicado: (2015)

Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma?
por: Modjtahedi, H, et al.
Publicado: (2005)

Generation of fusion protein EGFRvIII-HBcAg and its anti-tumor effect in vivo
por: Duan, Xiao-yi, et al.
Publicado: (2009)

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma
por: Babu, Ranjith, et al.
Publicado: (2012)

Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation
por: Kancha, Rama Krishna, et al.
Publicado: (2013)

EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors
por: Ellwanger, Kristina, et al.
Publicado: (2015)

Construction and Periplasmic Expression of the Anti-EGFRvIII ScFv Antibody Gene in Escherichia coli
por: Dewi, Kartika Sari, et al.
Publicado: (2016)

Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme
por: Newman, Jennifer P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_of0aqropqfkr1gq1d6sm1mefdd